Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Fatty liver disease, caused by the accumulation of fat in the liver, is estimated to affect one in four people worldwide. If ...

Researchers in Japan created an AI that can detect fatty liver disease from ordinary chest X-rays—an unexpected and low-cost ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

Altimmune shares rose 13% in premarket trading following an announcement it would present topline 24-week data from its Phase 2b trial evaluating pemvidutide as a treatment for those with metabolic ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.